Clinical Microbiology Market by Product (Instruments, Reagents), Specimen Type (Blood, Body fluids, Cerebrospinal Spinal Fluid), End-User, Application - Global Forecast 2024-2030
Description
Clinical Microbiology Market by Product (Instruments, Reagents), Specimen Type (Blood, Body fluids, Cerebrospinal Spinal Fluid), End-User, Application - Global Forecast 2024-2030
The Clinical Microbiology Market size was estimated at USD 7.80 billion in 2023 and expected to reach USD 8.68 billion in 2024, at a CAGR 10.91% to reach USD 16.12 billion by 2030.
Clinical microbiology encompasses a wide range of testing methods, and it is complex in terms of organisms and methods used to isolate & identify them. Clinical microbiology investigates microorganisms that cause infectious diseases and focuses on isolating and characterizing infectious organisms such as bacteria, viruses, parasites, and fungi to manage and treat patients. The increasing occurence of infectious diseases, growing awareness of disease prevention, and increasing healthcare expenditure are all factors driving the use of clinical microbiology. Problems concerning quality assurance and management in clinical microbiology laboratories coupled with limited availability of equipment and infrastructure can pose a challenge to product penetration in the market. Additionally, technological advancement in clinical microbiology instruments and processes presents various opportunities for medical laboratory businesses to expand their portfolio and increase profitability.
Regional Insights
In North America, the strong presence of leading market players, increasing investments in research & development, and the growing prevalence of infectious diseases significantly increase the adoption of clinical microbiology. Highly developed pharmaceutical and healthcare sectors in the United States are fueling the adoption of advanced clinical diagnostic techniques. Developing new and innovative microbiological technologies, such as targeted polymerase chain reactions (PCRs), to increase cost-effectiveness and improve clinical outcomes is strengthening the market growth of clinical microbiology across the region. In Asia-Pacific, the growing popularity of broad-range and molecular diagnosis to surge the sensitivity of diagnosis while promoting time effectiveness significantly contributes to the development of clinical microbiology. The booming medical tourism industry is expected to increase the need for microbial diagnostic and monitoring tests in Asian countries such as India, China, Thailand, and Malaysia. In the Europe region, the increasing prevalence of pathogenic diseases, growth in the discovery of adapting bacterium, and the rising need for speedy microbiological testing methods enhance the utilization of clinical microbiology technology.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Clinical Microbiology Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Increasing use of clinical microbiology in managing and controlling infectious diseases
- Favorable government and private organizations support, and initiatives in cancer diagnosis and research
- Market Restraints
- Limited availability of skilled professionals, equipment and infrastructure
- Market Opportunities
- Technological advancement in clinical microbiology products and processes
- Introduction of point-of-care microbiology testing
- Market Challenges
- Problems concerning quality assurance and management in clinical microbiology laboratories
- Market Segmentation Analysis
- Product: Use of laboratory instruments in clinical microbiology assessments
- Specimen Type: Preference for serum samples in serological testing to detect past or current infections
- End-User: Adoption of clinical microbiology in laboratories and research institutes to provide detailed insights about infectious disease conditions
- Application: Increasing use of clinical microbiology to diagnose gastrointestinal (GI) diseases by identifying causative pathogens
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Clinical Microbiology Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Clinical Microbiology Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Wichita State’s MDL Lab Shifting To Microbiology.
Wichita State University's Microbial Detection Laboratory (MDL) is set to shift its focus toward clinical microbiology to meet the growing demands of the healthcare industry. This new direction aligns with the MDL's core competencies, which includes the identification and control of microbial contaminants in food, water, and air. By expanding its expertise in clinical microbiology, the MDL is able to provide comprehensive testing and diagnostics for infectious diseases, in addition to its existing services. The laboratory's commitment to quality and precision sets it apart from others in the industry, making it a go-to resource for healthcare providers in need of reliable and efficient testing. This new development is a testament to the MDL's adaptability and commitment.
Cambridge Start-Up Won Funding To Develop New Diagnostics.
A Cambridge-based start-up company secured funding to develop advanced diagnostic tools for clinical microbiology. With the aim of revolutionizing the way bacterial infections are diagnosed and treated, the team of scientists and engineers at this innovative start-up are working toward creating a range of rapid and accurate tests that can identify and characterize infections in a few hours. With the potential to significantly improve patient outcomes and reduce the spread of antibiotic-resistant strains of bacteria, this development marks an exciting breakthrough for the field of clinical microbiology.
Transformative Agreement Signed Between The Microbiology Society And Indian Institute Of Science Bangalore
The Microbiology Society and the Indian Institute of Science (IISc) Bangalore have recently announced a groundbreaking Publish and Read agreement to enable open-access publishing to microbiologists worldwide, promoting knowledge sharing and enhancing researcher visibility and reputation.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Clinical Microbiology Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Clinical Microbiology Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Advanced Instruments, LLC, Agilent Technologies, Inc., B. Braun SE, Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMérieux S.A., Cardinal Health, Inc., Clinichem Ltd., COPAN Diagnostics Inc., Diagnóstica Longwood S.L., ELITech Group, F. Hoffmann-La Roche Ltd., Hardy Diagnostics, HORIBA, Ltd., Kyokuto Pharmaceutical Industrial Co., Ltd., Laboratorios Conda, S.A., Liofilchem S.r.l., Merck KGaA, Prestige Diagnostics U.K. Ltd., Pro Lab Diagnostics Inc., QIAGEN N.V., Rapid Micro Biosystems, Inc., Shimadzu Corporation, SSI Diagnostica A/S, TCS Biosciences Ltd., Thermo Fisher Scientific Inc., and Vircell S.L..
Market Segmentation & Coverage
This research report categorizes the Clinical Microbiology Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Instruments
- Reagents
- Specimen Type
- Blood
- Body fluids
- Cerebrospinal Spinal Fluid
- Fecal
- Saliva
- Serum
- Synovial Fluid
- Urine
- End-User
- Academic & Research Institutes
- Hospitals & Care Providers
- Laboratories
- Application
- Autoimmune Diseases
- Cardiology
- Diabetes
- Drug Testing
- Gastrointestinal Diseases
- Nephrology
- Oncology
- Periodontal Diseases
- Respiratory Diseases
- Sexually Transmitted Diseases
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing use of clinical microbiology in managing and controlling infectious diseases
- 5.1.1.2. Favorable government and private organizations support, and initiatives in cancer diagnosis and research
- 5.1.2. Restraints
- 5.1.2.1. Limited availability of skilled professionals, equipment and infrastructure
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancement in clinical microbiology products and processes
- 5.1.3.2. Introduction of point-of-care microbiology testing
- 5.1.4. Challenges
- 5.1.4.1. Problems concerning quality assurance and management in clinical microbiology laboratories
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Use of laboratory instruments in clinical microbiology assessments
- 5.2.2. Specimen Type: Preference for serum samples in serological testing to detect past or current infections
- 5.2.3. End-User: Adoption of clinical microbiology in laboratories and research institutes to provide detailed insights about infectious disease conditions
- 5.2.4. Application: Increasing use of clinical microbiology to diagnose gastrointestinal (GI) diseases by identifying causative pathogens
- 5.3. Market Trend Analysis
- 5.3.1. Presence of well-established market vendors with the ongoing development of advanced clinical microbiology testings
- 5.3.2. Prevalence of infectious disease and improvements in clinical microbiology products in APAC
- 5.3.3. Supportive government initiatives and ongoing research to overcome the burden of infectious diseases in the EMEA region
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter’s Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 6. Clinical Microbiology Market, by Product
- 6.1. Introduction
- 6.2. Instruments
- 6.3. Reagents
- 7. Clinical Microbiology Market, by Specimen Type
- 7.1. Introduction
- 7.2. Blood
- 7.3. Body fluids
- 7.4. Cerebrospinal Spinal Fluid
- 7.5. Fecal
- 7.6. Saliva
- 7.7. Serum
- 7.8. Synovial Fluid
- 7.9. Urine
- 8. Clinical Microbiology Market, by End-User
- 8.1. Introduction
- 8.2. Academic & Research Institutes
- 8.3. Hospitals & Care Providers
- 8.4. Laboratories
- 9. Clinical Microbiology Market, by Application
- 9.1. Introduction
- 9.2. Autoimmune Diseases
- 9.3. Cardiology
- 9.4. Diabetes
- 9.5. Drug Testing
- 9.6. Gastrointestinal Diseases
- 9.7. Nephrology
- 9.8. Oncology
- 9.9. Periodontal Diseases
- 9.10. Respiratory Diseases
- 9.11. Sexually Transmitted Diseases
- 10. Americas Clinical Microbiology Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Clinical Microbiology Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Clinical Microbiology Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Wichita State’s MDL Lab Shifting To Microbiology.
- 13.3.2. Cambridge Start-Up Won Funding To Develop New Diagnostics.
- 13.3.3. Transformative Agreement Signed Between The Microbiology Society And Indian Institute Of Science Bangalore
- 13.3.4. Hardy Diagnostics Awarded Manual Microbiology Agreement With Premier, Inc.
- 13.3.5. Department of Medical Microbiology Unveils Four New Projects Worth USD 6.8 Million and New Website.
- 13.3.6. ASM Funded for Inclusive Microbiology Leaders Program.
- 13.3.7. MAESTRIA, A New Generation Microbiology Middleware Developed by Biomérieux to Optimize Laboratory Workflow and Improve Patient Care.
- 13.3.8. Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Viral and Bacterial Infections.
- 13.3.9. BD Introduces Fully Automated Robotic Track System for Microbiology Labs.
- 13.3.10. FASTinov Collaborates with Beckman Coulter Life Sciences to Bring Ultra-Rapid 2h-AST Disruptive Technology to Clinical Microbiology Laboratories.
- 13.3.11. Upstate Planned To Launch A Multidisciplinary Lyme And Tick-Borne Disease Treatment Center.
- 13.3.12. Bio-Rad Expands QC Range for Abbott Diagnostic Platforms.
- 13.3.13. Federal Funds Set To Boost U of A’s Ability To Handle Highly Infectious Pathogens.
- 13.3.14. Oxford Gets £122m (USD 136.63 Million) Funding for Healthcare Research.
- 13.3.15. Sci-Tech Daresbury’s Perfectus Biomed Group Acquired by Global Medical Device Testing Leader NAMSA.
- 13.3.16. HORIBA Veterinary Adds New Rapid PCR Test for Difficult to Diagnose Parasite.
- 13.3.17. ValitaCell Joins Beckman Coulter Life Sciences.
- 13.3.18. Global Access Diagnostics Acquires Manufacturing Rights for IT-LEISH Rapid Diagnostic Test From Bio-Rad Laboratories.
- 13.3.19. SSI Diagnostica Continues a Strong Growth Journey.
- 13.3.20. BD, Accelerate Diagnostics Announce Global Commercial Collaboration.
- 13.3.21. SGS Launched New Microbiology Laboratory In Phoenix, Arizona.
- 13.3.22. Israel: EUR 22 Million (Usd 24.26 Million) EU Backing for Israeli Microbiology Diagnostic Player Pocared.
- 13.3.23. DCN Dx Acquires Microbiological Testing Products Company Biomed Diagnostics.
- 13.3.24. bioMérieux Strengthens its Commitment to Fight Antimicrobial Resistance with the Acquisition of Specific Diagnostics, An Innovative Company Focusing on Fast AST Solutions.
- 13.3.25. NIH Funded New Tuberculosis Research Advancement Centers.
- 13.3.26. Raue Advises Sonic Healthcare on the Acquisition of Diagnosticum Laboratory Group.
- 13.3.27. ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN.
- 13.3.28. Hardy Diagnostics Now Offers the BioCode MDx-3000.
- 13.3.29. Merck Announced Organizational Transformation of Life Science Business Sector To Strengthen Cdmo Offering And Accelerate Future Growth.
- 13.3.30. COPAN Diagnostics Announces Another Giant Step in the Evolution of Artificial Intelligence in Clinical Microbiology.
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
